This paper describes the design, construction and evaluation of a two-dimensional ultrasound phased array to be used in the treatment of benign prostatic hyperplasia. With two-dimensional phased arrays, the focal point position can be controlled by changing the electrical power and phase to the individual elements for focusing and electronically steering in a three-dimensional volume. The array was designed with a steering angle of +/-14 degrees in both transverse and longitudinal directions. A piezoelectric ceramic (PZT-8) was used as the material of the transducer, since it can handle the high power needed for tissue ablation and a matching layer was used for maximum acoustic power transmission to tissue. Analysis of the transducer ceramic and cable impedance has been designed for high power transfer with minimal capacitance and diameter. For this initial prototype, the final construction used magnet compatible housing and cabling for future application in a clinical magnetic resonance imaging system for temperature mapping of the focused ultrasound. To verify the capability of the transducer for focusing and steering, exposimetry was performed and the results correlated well with the calculated field. Ex vivo experiments were performed and indicated the capability of the transducer to ablate tissue using short sonications. For sonications with exposure time of 10, 15 and 20 s, the lesion size was roughly 1.8, 3.0 and 4.3 mm in diameter, respectively, which indicates the feasibility of this device.

Focused ultrasound surgery (FUS) is a clinical method for treating benign prostatic hyperplasia (BPH) in which tissue is noninvasively necrosed by elevating the temperature at the focal point above 60<th>°C using short sonications. With 1.75-dimensional (1.75-D) arrays, the power and phase to the individual elements can be controlled electronically for focusing and steering. This research describes the design, construction and evaluation of a 1.75-D ultrasound phased array to be used in the treatment of benign prostatic hyperplasia. The array was designed with a steering angle of ±13.5 deg in the transverse direction, and can move the focus in three parallel planes in the longitudinal direction with a relatively large focus size. A piezoelectric ceramic (PZT-8) was used as the material of the transducer and two matching layers were built for maximum acoustic power transmission to tissue. To verify the capability of the transducer for focusing and steering, exposimetry was performed and the results correlated well with the calculated fields. In vivo experiments were performed to verify the capability of the transducer to ablate tissue using short sonications. [Work supported by the Whitaker Foundation and the Department of Defense Congressionally Directed Medical Prostate Cancer Research Program.]

No abstract

BackgroundProstate cancer and benign prostatic hyperplasia are very common diseases in older American men, thus having a reliable treatment modality for both diseases is of great importance. The currently used treating options, mainly surgical ones, have numerous complications, which include the many side effects that accompany such procedures, besides the invasive nature of such techniques. Focused ultrasound is a relatively new treating modality that is showing promising results in treating prostate cancer and benign prostatic hyperplasia. Thus this technique is gaining more attention in the past decade as a non-invasive method to treat both diseases.MethodsIn this paper, the design, construction and evaluation of a 1.75 dimensional ultrasound phased array to be used for treating prostate cancer and benign prostatic hyperplasia is presented. With this array, the position of the focus can be controlled by changing the electrical power and phase to the individual elements for electronically focusing and steering in a three dimensional volume. The array was designed with a maximum steering angle of ± 13.5° in the transverse direction and a maximum depth of penetration of 11 cm, which allows the treatment of large prostates. The transducer piezoelectric ceramic, matching layers and cable impedance have been designed for maximum power transfer to tissue.ResultsTo verify the capability of the transducer for focusing and steering, exposimetry was performed and the results correlated well with the calculated field. Ex vivo experiments using bovine tissue were performed with various lesion sizes and indicated the capability of the transducer to ablate tissue using short sonications.ConclusionA 1.75 dimensional array, that overcame the drawbacks associated with one-dimensional arrays, has been designed, built and successfully tested. Design issues, such as cable and ceramic capacitances, were taken into account when designing this array. The final prototype overcame also the problem of generating grating lobes at unwanted locations by tapering the array elements.

This paper presents engineering progress and the latest in-vitro and in-vivo results obtained with a 4.0 MHz, 20 element, PZT annular transrectal HIFU array and several 4.0 MHz, 211 element, PZT and piezocomposite cylindrical transrectal HIFU arrays for the treatment of prostate cancer. The geometries of both arrays were designed and analyzed to steer the HIFU beams to the desired sites in the prostate volume using multi-channel electronic drivers, with the intent to increase treatment efficiency and reliability for the next generation of HIFU systems. The annular array is able to focus in depth from 25 mm to 50 mm, generate total acoustic powers in excess of 60W, and has been integrated into a modified Sonablate ® 500 HIFU system capable of controlling such an applicator through custom treatment planning and execution software. Both PZT-and piezocomposite cylindrical arrays were constructed and their characteristics were compared for the transrectal applications. These arrays have been installed into appropriate transducer housings, and have undergone characterization tests to determine their total acoustic power output, focusing range (in depth and laterally), focus quality, efficiency, and comparison tests to determine the material and technology of choice (PZT or piezocomposite) for intra-cavity HIFU applications. Array descriptions, characterization results, in-vitro and in-vivo results, and an overview of their intended use through the application software is shown.